References
Ferretti G, Bacchetti T, Johnston TP et al (2018) Lipoprotein(a): a missing culprit in the management of athero-thrombosis? J Cell Physiol 233:2966–2981. https://doi.org/10.1002/jcp.26050
Gragnano F, Calabrò P (2018) Role of dual lipid-lowering therapy in coronary atherosclerosis regression: evidence from recent studies. Atherosclerosis 269:219–228. https://doi.org/10.1016/j.atherosclerosis.2018.01.012
Fogacci F, Cicero AF, D’Addato S, D’Agostini L, Rosticci M, Giovannini M, Bertagnin E, Borghi C, Brisighella Heart Study Group (2017) Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study. Eur J Intern Med 37:49–55. https://doi.org/10.1016/j.ejim.2016.08.018
Scanu AM (1992) Lipoprotein(a): a genetic risk factor for premature coronary heart disease. JAMA, J Am Med Assoc 267:3326–3329. https://doi.org/10.1001/jama.267.24.3326
Rallidis LS, Pavlakis G, Foscolou A et al (2018) High levels of lipoprotein (a) and premature acute coronary syndrome. Atherosclerosis 269:29–34. https://doi.org/10.1016/j.atherosclerosis.2017.12.011
Marcucci R, Brunelli T, Fedi S et al (2005) Relevance of post-methionine homocysteine and lipoprotein (a) in evaluating the cardiovascular risk in young CAD patients. Eur J Clin Invest 35:1–7. https://doi.org/10.1111/j.1365-2362.2005.01439.x
Schwartz GG, Ballantyne CM, Barter PJ et al (2018) Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-outcomes randomized clinical trial. JAMA Cardiol 3:164–168. https://doi.org/10.1001/jamacardio.2017.3833
Milionis HJ, Filippatos TD, Loukas T et al (2006) Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis 187:170–176. https://doi.org/10.1016/j.atherosclerosis.2005.08.036
Tsimikas S (2017) A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 69:692–711. https://doi.org/10.1016/j.jacc.2016.11.042
Chiarugi L, Prisco D, Antonucci E et al (2001) Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty. Atherosclerosis 154:129–135
Catapano AL, Graham I, De Backer G et al (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37:2999–3058l. https://doi.org/10.1093/eurheartj/ehw272
Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S (2019) Relationship between low-density lipoprotein cholesterol and lipoprotein(a) lowering in response to PCSK9 inhibition with evolocumab. J Am Heart Assoc 8:e010932. https://doi.org/10.1161/JAHA.118.010932
Gragnano F, Natale F, Concilio C et al (2018) Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience. J Cardiovasc Med 19:75–77. https://doi.org/10.2459/JCM.0000000000000611
Schettler VJJ, Neumann CL, Peter C et al (2017) Current insights into the German lipoprotein apheresis registry (GLAR)—almost 5 years on. Atheroscler Suppl 30:50–55. https://doi.org/10.1016/j.atherosclerosissup.2017.05.006
Viney NJ, van Capelleveen JC, Geary RS et al (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388:2239–2253. https://doi.org/10.1016/S0140-6736(16)31009-1
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of human and animal rights
The study was carried out according to Declaration of Helsinki.
Informed consent
Patients gave their informed consent to participate to the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gragnano, F., Fimiani, F., Di Maio, M. et al. Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. Intern Emerg Med 14, 621–625 (2019). https://doi.org/10.1007/s11739-019-02082-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-019-02082-8